Repligen Co. (NASDAQ:RGEN) Expected to Announce Quarterly Sales of $63.01 Million

Equities research analysts expect Repligen Co. (NASDAQ:RGEN) to announce sales of $63.01 million for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Repligen’s earnings, with estimates ranging from $56.00 million to $70.06 million. Repligen reported sales of $47.73 million during the same quarter last year, which indicates a positive year over year growth rate of 32%. The firm is expected to report its next quarterly earnings results on Thursday, August 1st.

According to Zacks, analysts expect that Repligen will report full-year sales of $254.96 million for the current financial year, with estimates ranging from $245.10 million to $265.60 million. For the next year, analysts expect that the business will post sales of $299.10 million, with estimates ranging from $285.00 million to $314.05 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Repligen.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.26 by $0.02. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The business had revenue of $60.63 million for the quarter, compared to analysts’ expectations of $55.09 million. During the same period in the previous year, the company posted $0.17 EPS. Repligen’s revenue was up 35.3% on a year-over-year basis.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a research note on Thursday. BidaskClub lowered shares of Waterstone Financial from a “hold” rating to a “sell” rating in a research note on Friday, June 21st. Finally, ValuEngine raised shares of United Overseas Bank from a “sell” rating to a “hold” rating in a research note on Monday, June 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Repligen has an average rating of “Buy” and an average price target of $72.00.

Shares of RGEN stock traded down $0.99 on Monday, hitting $86.80. The company’s stock had a trading volume of 310,761 shares, compared to its average volume of 603,326. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.18 and a quick ratio of 1.84. Repligen has a fifty-two week low of $45.00 and a fifty-two week high of $89.22. The firm’s fifty day moving average price is $80.78. The firm has a market cap of $4.15 billion, a PE ratio of 118.90, a price-to-earnings-growth ratio of 5.30 and a beta of 1.10.

In other Repligen news, Director Glenn L. Md Cooper sold 5,000 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the completion of the transaction, the director now owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Karen A. Dawes sold 1,295 shares of the business’s stock in a transaction on Monday, June 17th. The stock was sold at an average price of $77.35, for a total transaction of $100,168.25. Following the transaction, the director now directly owns 118,329 shares of the company’s stock, valued at approximately $9,152,748.15. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in RGEN. Royce & Associates LP raised its position in shares of Repligen by 40.6% during the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 145 shares during the last quarter. Falcon Point Capital LLC raised its position in shares of Repligen by 2.5% during the first quarter. Falcon Point Capital LLC now owns 6,922 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 167 shares during the last quarter. Advisory Services Network LLC raised its position in shares of Repligen by 10.7% during the fourth quarter. Advisory Services Network LLC now owns 1,771 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 171 shares during the last quarter. Arizona State Retirement System raised its position in shares of Repligen by 0.3% during the first quarter. Arizona State Retirement System now owns 60,301 shares of the biotechnology company’s stock valued at $3,563,000 after buying an additional 188 shares during the last quarter. Finally, Bronfman E.L. Rothschild L.P. raised its position in shares of Repligen by 16.8% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 214 shares during the last quarter. 85.53% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Featured Article: Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on Repligen (RGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.